Literature DB >> 21595597

Indications and safety of intravenous and subcutaneous immunoglobulin therapy.

Nima Rezaei1, Hassan Abolhassani, Asghar Aghamohammadi, Hans D Ochs.   

Abstract

Immunoglobulin (Ig) therapy is an important method of treatment for a number of immunological, hematological, neurological and dermatological disorders. Over the years, the range of indications in which Ig therapy, either replacement or immunomodulatory, is effective has substantially increased. Although Ig therapy was originally limited to intramuscular injection, intravenous infusion has became the most frequent route of administration, followed by subcutaneous injection. This article presents current information on indications, mechanisms of action, efficacy and practical aspects of intravenous and subcutaneous Ig replacement/immunomodulatory therapy as well as associated adverse reactions.

Mesh:

Substances:

Year:  2011        PMID: 21595597     DOI: 10.1586/eci.10.104

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  10 in total

1.  Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

Authors:  Asghar Aghamohammadi; Payam Mohammadinejad; Hassan Abolhassani; Babak Mirminachi; Masoud Movahedi; Mohammad Gharagozlou; Nima Parvaneh; Vaheid Zeiaee; Bahram Mirsaeed-Ghazi; Zahra Chavoushzadeh; Alireza Mahdaviani; Mahboubeh Mansouri; Sedigheh Yousefzadegan; Bahareh Sharifi; Fariborz Zandieh; Ehsan Hedayat; Ali Nadjafi; Roya Sherkat; Behzad Shakerian; Mahnaz Sadeghi-Shabestari; Reza Farid Hosseini; Farahzad Jabbari-Azad; Hamid Ahanchian; Fatemeh Behmanesh; Mohammadreza Zandkarimi; Afshin Shirkani; Taher Cheraghi; Abbas Fayezi; Iraj Mohammadzadeh; Reza Amin; Soheila Aleyasin; Mojgan Moghtaderi; Javad Ghaffari; Saba Arshi; Naser Javahertrash; Mohammad Nabavi; Mohammad Hassan Bemanian; Alireza Shafiei; Najmedin Kalantari; Akefeh Ahmadiafshar; Hossein Ali Khazaei; Lida Atarod; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

Review 2.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

3.  Evidence that NF-κB and MAPK Signaling Promotes NLRP Inflammasome Activation in Neurons Following Ischemic Stroke.

Authors:  David Yang-Wei Fann; Yun-An Lim; Yi-Lin Cheng; Ker-Zhing Lok; Prasad Chunduri; Sang-Ha Baik; Grant R Drummond; S Thameem Dheen; Christopher G Sobey; Dong-Gyu Jo; Christopher Li-Hsian Chen; Thiruma V Arumugam
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

4.  Novel approaches in the treatment of myositis and myopathies.

Authors:  Jemima Albayda; Lisa Christopher-Stine
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

5.  Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita.

Authors:  Misa Hirose; Benjamin Tiburzy; Norito Ishii; Elena Pipi; Sabina Wende; Ellen Rentz; Falk Nimmerjahn; Detlef Zillikens; Rudolf A Manz; Ralf J Ludwig; Michael Kasperkiewicz
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

Review 6.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

7.  Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.

Authors:  Masato Takeuchi; Shuichi Ito; Masaki Nakamura; Koji Kawakami
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 8.  New Frontiers in Subcutaneous Immunoglobulin Treatment.

Authors:  Stephen Jolles; Mark R Stein; Hilary J Longhurst; Michael Borte; Bruce Ritchie; Matthias H Sturzenegger; Melvin Berger
Journal:  Biol Ther       Date:  2011-12-14

9.  Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.

Authors:  Hosein Shabaninejad; Asra Asgharzadeh; Aziz Rezapour; Nima Rezaei
Journal:  Med J Islam Repub Iran       Date:  2017-12-17

10.  Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?

Authors:  Fateme Babaha; Nima Rezaei
Journal:  Am J Med Sci       Date:  2020-07-29       Impact factor: 2.378

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.